Non-Hodgkin Lymphoma
News
New treatment option for relapsed/refractory NHL
Results of the phase 3 GADOLIN trial have revealed a new treatment option for patients with relapsed/refractory non-Hodgkin lymphoma (NHL),...
News
Predicting drug’s efficacy in relapsed DLBCL
The histone deacetylase inhibitor panobinostat can produce durable responses in certain patients with relapsed diffuse large B-cell lymphoma (...
News
Drug no longer in development for DLBCL, other cancers
ProNAi Therapeutics recently announced its decision to stop development of PNT2258, a drug designed to treat cancers characterized by...
News
Research provides new insight into CLL
New research explains how an inherited genetic variant associated with an increased risk of chronic lymphocytic leukemia (CLL) helps cancer cells...
News
CAR T-cell therapy granted orphan designation
Photo courtesy of NIAID The US Food and Drug Administration (FDA) has granted orphan drug designation for a CD4-directed chimeric antigen receptor...
News
Antibody prevents migration of lymphoma cells
Preclinical research suggests a novel antibody can inhibit the migration of lymphoma cells and stop the cells from proliferating. “Since they...
News
SB-generated CAR T cells show promise
Image by NIAID Researchers have reported “favorable” long-term results from a pair of phase 1 trials in which they used the non-viral Sleeping...
News
Compounds can fight lymphoma, other cancers
Image by Ed Uthman Preclinical research suggests a novel class of compounds are effective against pediatric and adult cancers, including lymphoma...
News
Lenalidomide maintenance doesn’t improve OS in DLBCL
Photo courtesy of Celgene Initial results from the phase 3 REMARC study suggest that lenalidomide (Revlimid) maintenance does not prolong overall...
News
EC grants immunotherapy orphan designation
among uninfected cells (blue) Image courtesy of Benjamin Chaigne-Delalande The European Commission (EC) has granted orphan drug designation for...
News
Ibrutinib approved for first-line treatment of CLL
Photo courtesy of Janssen Health Canada has approved the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica®) as a first-line treatment for...